Related Experiment Video

Updated: Aug 13, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

M S Neshat1, I K Mellinghoff, C Tran

  • 1Department of Medicine, University of California School of Medicine, Los Angeles, CA 90095, USA.

Proceedings of the National Academy of Sciences of the United States of America
|August 16, 2001
PubMed

Insights

PTEN-deficient cancers show sensitivity to FRAP/mTOR inhibitors like CCI-779. This study highlights FRAP/mTOR as a therapeutic target in PTEN-null tumors, offering new treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The phosphatidyl inositol 3-kinase/Akt pathway is frequently upregulated in cancers due to PTEN loss.
  • FRAP/mTOR kinase is a key downstream effector in this signaling pathway.

Purpose of the Study:

  • To investigate the sensitivity of PTEN-deficient cancer cells to FRAP/mTOR inhibition using CCI-779.
  • To determine the role of FRAP/mTOR in tumorigenesis driven by PTEN loss and Akt activation.

Main Methods:

  • In vitro and in vivo studies using isogenic PTEN(+/+) and PTEN(-/-) mouse cells.
  • Analysis of human cancer cells with defined PTEN status.
  • Biochemical assays to assess FRAP/mTOR pathway activation (e.g., S6 kinase activity, S6 phosphorylation).

Main Results:

  • PTEN-null cancer cells exhibited preferential growth inhibition by pharmacologic FRAP/mTOR inhibition.
  • CCI-779 treatment reversed enhanced tumor growth caused by constitutive Akt activation in PTEN(+/+) cells.
  • Loss of PTEN correlated with increased S6 kinase activity and ribosomal S6 phosphorylation, indicating FRAP/mTOR pathway activation.

Conclusions:

  • FRAP/mTOR functions downstream of Akt in tumorigenesis.
  • PTEN-null human cancers are potential candidates for FRAP/mTOR inhibitor therapy.
  • Differential sensitivity to CCI-779 was not due to differences in pathway blockade.

More Related Videos

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...